Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Old Dominion Freight Line Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Old Dominion Freight Line Inc trades at $227.63 (market cap $47.34B). The key difference: Old Dominion Freight Line Inc is the larger of the two by market cap, and Old Dominion Freight Line Inc pays a 0.51% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ODFL | |
|---|---|---|
Market Cap | $39.89B | $47.34B |
Sector | Health | Industrials |
52-Week High | $491.22 | $248.73 |
52-Week Low | $278.09 | $126.29 |
Enterprise Value | $38.15B | $47.09B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ODFL trades at $227.63, up 0.79% today, near its consensus price target of $231.29. The stock shows bullish technical signals with strong moving averages, though RSI indicates mild overbought conditions. Fundamentally, ODFL maintains high profitability with an 18.46% net margin and 23.33% ROE, but valuation ratios like P/E of 47.52 are elevated. Recent earnings beats and a solid balance sheet with minimal debt support its quality, while news highlights mixed sentiment amid freight market recovery and competitive pressures from Amazon's LTL expansion.
Outlook: ODFL offers a high-quality play on freight recovery with robust fundamentals, but rich valuation and near-term headwinds warrant caution. Upside depends on Q2 2026 earnings meeting the $1.51 EPS estimate. Risks include economic sensitivity and rising competition. Analyst consensus is mixed with 33% buy ratings, suggesting patience for better entry points may be prudent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
